Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

Medexus Pharmaceuticals (TSX:MDP) has revealed that the U.S. Food and Drug Administration has extended the review period for ...

FCR, a standard treatment for younger and fitter patients for over a decade, is a combination of the chemotherapy drugs fludarabine (Fludara) and cyclophosphamide (Cytoxan) plus the monoclonal ...

Medexus Pharmaceuticals Inc. Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – September 16, 2024) – Medexus ...

Haematological diseases are pathological conditions primarily affecting the blood or blood-producing organs. This group of disorders includes, but is not limited to, various types of anaemia ...

The treatment landscape of chronic lymphocytic leukaemia (CLL) was transformed when the small molecule drug ibrutinib ...

The goal of HCT is to cure an underlying malignancy or hematologic disorder. The procedure can be performed in an inpatient ...

The company has since decided to add fludarabine as a conditioning agent to boost responses, even though this practice came under suspicion when deaths occurred in Juno’s CAR-T trials.

Chronic pain management physicians and patients are always looking for long-term solutions rather than short-lived interventions. There are three main nonsurgical modalities to ablate nervous ...